| scholarly article | Q13442814 |
| P50 | author | Tom H Karlsen | Q93051413 |
| Kirsten Muri Boberg | Q113457819 | ||
| P2093 | author name string | M Vesterhus | |
| P2860 | cites work | Primary biliary cirrhosis | Q56428273 |
| FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis | Q57155136 | ||
| Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations | Q58021206 | ||
| A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis | Q22004274 | ||
| Bile acids: natural ligands for an orphan nuclear receptor | Q22010063 | ||
| Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease | Q24322810 | ||
| Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis | Q24633290 | ||
| Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants | Q24633806 | ||
| High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis | Q24655731 | ||
| The genetics of complex cholestatic disorders | Q26992279 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis | Q28237152 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis | Q28263151 | ||
| A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis | Q28264570 | ||
| Lysophosphatidic acid is a potential mediator of cholestatic pruritus | Q28285205 | ||
| Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study | Q28290823 | ||
| Effects of long-term rifampicin administration in primary biliary cirrhosis | Q28319860 | ||
| Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis | Q28943317 | ||
| Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population | Q28943429 | ||
| Host-gut microbiota metabolic interactions | Q29615104 | ||
| ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study | Q30454106 | ||
| Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice | Q30535328 | ||
| A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults | Q33368134 | ||
| Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant | Q33730935 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| The immunobiology and pathophysiology of primary biliary cirrhosis | Q34324185 | ||
| Epidemiology of primary sclerosing cholangitis | Q34329821 | ||
| Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis | Q34351552 | ||
| Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients | Q34462959 | ||
| Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. | Q34504976 | ||
| Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis | Q34524586 | ||
| Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials | Q34550505 | ||
| Modulation of the fecal bile acid profile by gut microbiota in cirrhosis | Q34554908 | ||
| Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches | Q34623557 | ||
| What an endoscopist should know about immunoglobulin-G4-associated disease of the pancreas and biliary tree | Q34634666 | ||
| Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens | Q44505156 | ||
| Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity | Q44552108 | ||
| Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival | Q44836185 | ||
| Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis | Q45045457 | ||
| Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. | Q45289722 | ||
| Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial | Q45309693 | ||
| Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis | Q45839711 | ||
| Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis | Q45877492 | ||
| Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. | Q45935772 | ||
| Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis. | Q46066772 | ||
| New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. | Q46098794 | ||
| Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome | Q46391510 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid | Q46521938 | ||
| High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective | Q46722756 | ||
| Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome | Q46852534 | ||
| Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis | Q48516720 | ||
| Screening for liver cancer: the rush to judgment | Q48718280 | ||
| Quality of life before and after liver transplantation for cholestatic liver disease | Q48773263 | ||
| IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis | Q50173871 | ||
| Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. | Q50636830 | ||
| Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort. | Q51038177 | ||
| Diagnosis and management of primary sclerosing cholangitis. | Q51726466 | ||
| Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. | Q52933260 | ||
| Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. | Q53527400 | ||
| Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. | Q53711274 | ||
| Molecular pathogenesis of cholestasis. | Q54344101 | ||
| Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. | Q54572984 | ||
| Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. | Q55036188 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Pruritus in cholestasis: facts and fiction. | Q38210112 | ||
| Mucosal IgG4 cell infiltration in ulcerative colitis is linked to disease activity and primary sclerosing cholangitis | Q38397062 | ||
| The natural history of small-duct primary sclerosing cholangitis | Q38457100 | ||
| Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. | Q39275409 | ||
| Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid | Q39293482 | ||
| Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy | Q39891944 | ||
| PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide | Q39896398 | ||
| Differential effects of norUDCA and UDCA in obstructive cholestasis in mice | Q40606268 | ||
| The true impact of fatigue in primary biliary cirrhosis: a population study | Q40643274 | ||
| Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease | Q41114391 | ||
| Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. | Q42623837 | ||
| The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: Results of a 9year follow-up | Q42923603 | ||
| Recurrence and rejection in liver transplantation for primary sclerosing cholangitis | Q43046283 | ||
| Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone | Q43086793 | ||
| Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines | Q43253298 | ||
| High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? | Q43284332 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis | Q43542102 | ||
| High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis | Q43618408 | ||
| Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study | Q43725734 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study | Q43915265 | ||
| Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis | Q43995541 | ||
| Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation | Q44169502 | ||
| The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort. | Q44293400 | ||
| Simplified criteria for the diagnosis of autoimmune hepatitis | Q44425899 | ||
| Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid | Q34650472 | ||
| Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis | Q34672135 | ||
| Update on primary sclerosing cholangitis | Q34679405 | ||
| Gallbladder polyps in primary sclerosing cholangitis: not so benign | Q34769659 | ||
| Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? | Q35030826 | ||
| Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence | Q35182259 | ||
| Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma | Q35659525 | ||
| Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis | Q35823397 | ||
| Long-term immunosuppression for prevention of nonviral disease recurrence | Q36141152 | ||
| Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis | Q36495172 | ||
| Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis | Q36589269 | ||
| Towards common denominators in primary biliary cirrhosis: the role of IL-12 | Q36632355 | ||
| The TGR5 receptor mediates bile acid-induced itch and analgesia | Q36733406 | ||
| Congenital cholestatic syndromes: what happens when children grow up? | Q37008383 | ||
| Gallstone disease: from genes to evidence-based therapy | Q37097509 | ||
| Antimitochondrial antibody-negative primary biliary cirrhosis | Q37154313 | ||
| Triggers and drivers of autoimmunity: lessons from coeliac disease | Q37283086 | ||
| Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis--overlapping or separate diseases? | Q37511276 | ||
| Genetics of cholestatic liver disease in 2010. | Q37665141 | ||
| Recurrent primary biliary cirrhosis after liver transplantation | Q37701934 | ||
| Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis | Q37760788 | ||
| The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies | Q37781024 | ||
| Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue | Q37808546 | ||
| Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature | Q37824300 | ||
| Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis | Q37836238 | ||
| Liver transplantation in PBC and PSC: indications and disease recurrence | Q37860618 | ||
| New treatment strategies for primary sclerosing cholangitis | Q37892297 | ||
| The itch of liver disease | Q37902319 | ||
| Primary sclerosing cholangitis and malignancy | Q37960969 | ||
| Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis | Q37963978 | ||
| Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update | Q38028619 | ||
| Bile acid transporters and regulatory nuclear receptors in the liver and beyond | Q38033967 | ||
| Primary biliary cirrhosis and bile acids | Q38058979 | ||
| TGR5 in cholangiocytes | Q38083494 | ||
| Mucosal immunity in liver autoimmunity: a comprehensive review | Q38124568 | ||
| Novel insights into autoimmune liver diseases provided by genome-wide association studies | Q38127957 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ascending cholangitis | Q603644 |
| primary sclerosing cholangitis | Q1058608 | ||
| primary biliary cholangitis | Q1072420 | ||
| P304 | page(s) | 282-301 | |
| P577 | publication date | 2013-12-29 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis | |
| P478 | volume | 39 |
| Q35470575 | A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. |
| Q40110162 | A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. |
| Q40870367 | Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value |
| Q40866681 | Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report |
| Q26766699 | Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver |
| Q27691276 | Clinical Characteristics of Concomitant Systemic Lupus Erythematosus and Primary Biliary Cirrhosis: A Literature Review |
| Q88300304 | Clinical connection between rheumatoid arthritis and liver damage |
| Q53728128 | Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. |
| Q54040784 | Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. |
| Q90722936 | Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities |
| Q50939070 | Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. |
| Q39178438 | Genetics of primary sclerosing cholangitis and pathophysiological implications |
| Q42151602 | Indications and Outcomes in Liver Transplantation in Patients With Primary Sclerosing Cholangitis in Norway |
| Q26782863 | Liver Transplantation for Patients with Cholestatic Liver Diseases |
| Q52601601 | MR elastography in primary sclerosing cholangitis: correlating liver stiffness with bile duct strictures and parenchymal changes. |
| Q35796897 | MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma |
| Q40989271 | Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD. |
| Q37740241 | Patients with primary sclerosing cholangitis require more sedation during endoscopic retrograde cholangiography |
| Q26781780 | Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective |
| Q26744040 | Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management |
| Q24658446 | Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q38417642 | Primary sclerosing cholangitis - the Norwegian experience |
| Q26774539 | Recurrence of autoimmune liver diseases after liver transplantation |
| Q38974002 | Reversal of liver cirrhosis: current evidence and expectations |
| Q35942610 | The Cholangiopathies |
| Q40355263 | The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience |
| Q35958534 | Therapeutic targeting of bile acids |
| Q57113373 | Treating constipation with bile: a new target |
| Q53728658 | Ultrasound and Point Shear Wave Elastography in Livers of Patients with Primary Sclerosing Cholangitis. |
| Q33840969 | Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications? |
Search more.